Micropharma
- Company typePrivate
- Founded2004
- HeadquartersMontréal, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Micropharma does
Micropharma is a privately held Canadian biotechnology company founded in 2004 and headquartered in Montréal, Quebec. According to firmographic data, the company develops biotherapeutics, diagnostics, and medical devices targeting metabolic diseases, and operates with a small team of 11–50 employees. The entity is described as operating, with no public ticker and no disclosed parent company or subsidiaries.
The company's only disclosed capital event is a single funding round of approximately $851,242 closed on January 24, 2013, with unknown investors and no identified lead. Leadership comprises CEO Ryan Jones, founder and co-founder Satya Prakash, and director Robert Semmens. No patents, trademarks, products, services, partnerships, regulatory actions, or AI/ML capabilities are disclosed in the available source data.
The current website at micropharma.net displays Japanese-language WordPress blog content on nursing workplace confidence topics, which is materially inconsistent with the firmographic description of a metabolic-disease biotech. This anomaly — between a Montréal biotech profile and a Japanese-language nursing content blog — suggests either a domain lapse and repurchase, a pivot, or a data-aggregation error in the firmographic feed. No recent operating milestones, product launches, or commercial activity are disclosed.
Micropharma firmographics
Firmographics- Name
- Micropharma
- Website
- https://micropharma.net
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Micropharma industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Engineered Microbial Therapeutics (synthetic biology, gene circuits) (HLAAAFAD)
- akta.pro secondary industries
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD), Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)
Keywords
Where Micropharma is headquartered
LocationHeadquarters
- HQ city
- Montréal
- HQ country
- Canada
- HQ region
- North America
Markets served
Micropharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations
Marketing channels1 record
Micropharma product offering
Product offeringCore offering
Micropharma develops biotherapeutics, diagnostics, and medical devices targeted at metabolic diseases. The company operates as a small private biopharmaceutical and medical device firm headquartered in Montréal, Canada, with 11-50 employees, focused on therapeutic, diagnostic, and device product development for metabolic conditions.
Differentiator
Problem solved
Functional benefit
Companies that use Micropharma
Customer profileSegments1 record
Ideal customer profiles1 record
Micropharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Micropharma partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights1 record
Micropharma competitors and assessment
Company assessmentDirect peers
- Seres Therapeutics: Clinical-stage developer of engineered microbiome-based biotherapeutics for metabolic and inflammatory diseases. Directly comparable to Micropharma's stated biotherapeutics-for-metabolic-disease positioning.
- Vedanta Biosciences: Develops defined-consortium live biotherapeutic products for metabolic, autoimmune, and infectious diseases. Closely aligned with Micropharma's claimed engineered microbial therapeutic platform.
- Novome Biotechnologies: Engineered microbial therapeutics company focused on metabolic diseases including hyperoxaluria. Shares Micropharma's biotherapeutic-plus-metabolic-disease niche.
- Second Genome: Microbiome-based therapeutic developer using synthetic biology approaches to target metabolic and inflammatory conditions. Comparable in modality and disease focus.
- Enterome: Develops microbiome-derived small molecules and engineered microbial candidates for metabolic and immune-mediated diseases. Directly comparable biotherapeutic platform.
- Finch Therapeutics: Microbiome therapeutics company developing whole-microbiome and engineered consortia products for metabolic and gastrointestinal indications.
- MetaboGen: Swedish microbiome-derived biotherapeutics company focused on metabolic and liver diseases. Direct overlap in therapeutic area and microbial therapeutic modality.
Emerging players
- Kaleido Biosciences: Targeted microbe-derived and synthetic biology-based interventions for metabolic and inflammatory diseases. Closely comparable to Micropharma's stated pipeline direction.
- Aprea Therapeutics: Small-molecule and biologic developer with programs in metabolic and cancer indications; comparable as a small-cap biotherapeutic developer pursuing metabolic diseases.
Broad incumbents
- BioGaia: Established probiotics and microbiome-based product company with metabolic and gastrointestinal health products. Comparable as a broader microbiome health/biotherapeutic platform.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat1 record
Key risks5 records
Key highlights3 records
Customer concentration
Micropharma social profiles
Digital presenceMicropharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Micropharma leadership team
Management profileNumber of profiles
Profiles3 records
Micropharma funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Micropharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Micropharma
What does Micropharma do?
Micropharma develops biotherapeutics, diagnostics, and medical devices targeted at metabolic diseases. The company operates as a small private biopharmaceutical and medical device firm headquartered in Montréal, Canada, with 11-50 employees, focused on therapeutic, diagnostic, and device product development for metabolic conditions.
Is Micropharma a public or private company?
Micropharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was Micropharma founded?
Micropharma was founded in 2004. It employs 11 to 50 people.
Where is Micropharma based?
Micropharma is headquartered in Montréal, Canada, in the North America region.
Who are Micropharma's main competitors?
Direct peers on record are Seres Therapeutics, Vedanta Biosciences, Novome Biotechnologies, Second Genome, Enterome, Finch Therapeutics and MetaboGen. Emerging players are Kaleido Biosciences and Aprea Therapeutics. BioGaia is listed as a broad incumbent.
Does Micropharma have an API?
No public API is recorded for Micropharma.
What industry is Micropharma in?
Micropharma's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAFAD, Engineered Microbial Therapeutics (synthetic biology, gene circuits), with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 541714 and its SIC code is 2836.